Multiple Myeloma CAR T-Cell Therapy: A 2026 Referral Roadmap

Introduction: Why Timing and Referral Knowledge Matter More Than Ever

Many people living with multiple myeloma, and the family members who support them, are unaware that CAR T-cell therapy is available to them. Others have heard of it but assume it is a last-resort option, used only after every other treatment has failed. In 2026, that assumption can cost patients valuable time.

CAR-T is now recommended much earlier in the treatment timeline, particularly for patients whose disease no longer responds to lenalidomide. As a result, the question of when to seek a referral is an urgent, practical decision, not something to set aside for the distant future.

This article does not compare Abecma and Carvykti in clinical detail. It is a step-by-step roadmap covering when to ask about CAR-T, what to say, what happens next, and how to prepare logistically and financially.

The need for this information is significant. According to the American Cancer Society, about 36,000 new multiple myeloma cases are expected in the United States in 2026. The five-year survival rate has nearly doubled since the mid-1990s, rising from 32% to 62%. Immunotherapies such as CAR-T are part of the reason. Patients benefit most from that progress when they can reach these therapies at the right time.

Multiple Myeloma CAR T-Cell Therapy in 2026: The Landscape

CAR T-cell therapy uses the patient’s own immune system to fight cancer. Doctors collect T cells (a type of white blood cell) from the patient’s blood. A laboratory then engineers those cells to recognize a protein called BCMA (B-cell maturation antigen), which appears on the surface of myeloma cells. After manufacturing, the modified cells are infused back into the patient, where they seek out and attack the cancer.

This approach works differently from other myeloma treatments:

• Chemotherapy kills rapidly dividing cells broadly.
• Stem cell transplant uses high-dose chemotherapy followed by a rescue of blood-forming cells.
• Maintenance therapy involves ongoing medication to keep the disease in check.

CAR-T, by contrast, is typically a one-time infusion of a living, personalized treatment.

Two BCMA-directed CAR-T products are FDA-approved for relapsed or refractory multiple myeloma:

• Idecabtagene vicleucel (Abecma)
• Ciltacabtagene autoleucel (Carvykti)

Both were first approved as fifth-line treatments. In 2024, the FDA expanded their use to earlier lines of therapy:

• Abecma was approved for relapsed or refractory disease after two or more prior lines of therapy, including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody. This approval was based on the KarMMa-3 trial.
• Carvykti became the first BCMA-targeted therapy approved for second-line use. It is indicated for patients who have received at least one prior line of therapy, including a PI and an IMiD, and who are refractory to lenalidomide. In the CARTITUDE-4 study, Carvykti reduced the risk of disease progression or death by 59% compared with standard therapies.

The field continues to change quickly. More than 170 clinical trials of CAR-T in multiple myeloma are registered worldwide. A next-generation product, anitocabtagene autoleucel, has an FDA action date of December 23, 2026. For patients, the key point is that options are growing, and knowing how to access them matters as much as knowing they exist.

When Does CAR-T Become Relevant? Mapping the Decision Points

The Traditional Model

In the past, CAR-T was considered only after a patient had relapsed several times and had exhausted multiple classes of drugs. Many patients reached that point in fragile health, which limited both their eligibility and their outcomes.

The 2026 Shift

The National Comprehensive Cancer Network (NCCN) now recommends referral for CAR-T evaluation as early as the second line of therapy for patients with lenalidomide-refractory disease. This is a major change. Patients and caregivers should feel comfortable asking about it directly.

Red Flags That Should Trigger a Referral Conversation

Patients should consider requesting a CAR-T evaluation if any of the following apply:

• Lenalidomide-refractory status (the disease progressed while on lenalidomide)
• Anti-CD38-refractory status (for example, the disease no longer responds to daratumumab or isatuximab)
• High-risk cytogenetics identified through genetic testing of the myeloma cells
• Extramedullary disease (myeloma growing outside the bone marrow)
• Early relapse after first-line therapy
• Rapid functional decline in daily health or physical ability

Don’t Wait Until You Get There

Experts increasingly urge community oncologists to refer patients for CAR-T evaluation as early as the first relapse. Referral and evaluation can often proceed alongside current treatment without pausing it. If the current regimen produces a response, that response can later be consolidated with CAR-T.

Referral Is Not a Commitment

A referral for evaluation does not mean a patient must begin CAR-T right away. It starts a process of eligibility screening, testing, and planning. Patients keep their options open while gaining time and information.

The Referral Conversation: What to Say to a Community Oncologist

Patients do not need to be clinical experts to have a productive conversation about CAR-T. Using specific language, however, tells the oncologist that the patient is requesting a formal evaluation at a CAR-T center, not just general reassurance.

Sample Phrasing

Patients and caregivers might say:

• “Does my disease status, such as being lenalidomide-refractory or having high-risk cytogenetics, meet the current NCCN criteria for CAR-T referral?”
• “I’d like a referral to a CAR-T-certified treatment center for evaluation, not just a general specialist opinion.”

Pointed Questions Worth Asking

• “Given my relapse history, am I a candidate for CAR-T under the updated guidelines?”
• “Can you refer me now for evaluation, even if I continue my current treatment in the meantime?”

Why Specificity Matters

Community oncologists manage many treatment options and many cancer types. Unless prompted, they may not raise CAR-T, especially if they are less familiar with the newer earlier-line approvals. A direct question helps ensure the topic gets a clear answer.

Keep the Process Moving

Patients should ask for a copy of the referral notes, or at least a timeline for when the referral will be sent. Following up with the receiving center a few days later helps confirm the paperwork arrived.

Self-Advocacy: What to Do If CAR-T Hasn’t Been Raised as an Option

Many patients learn about CAR-T from advocacy groups or their own research before their oncologist mentions it. This is especially common outside major academic centers, and it is a normal part of the process.

If CAR-T has not come up, patients can:

• Request a second opinion at a CAR-T-certified cancer center.
• Contact a center directly. Most major centers accept inquiries from patients in addition to physician referrals.
• Bring documentation to appointments, including:
  • A summary of prior treatments and dates
  • Refractory status to specific drug classes
  • A reference to the NCCN second-line referral update

Advocating for oneself can feel uncomfortable. It is appropriate and expected, however. Raising CAR-T is not a criticism of the current oncologist’s care; it is a request to explore every available option.

Independent organizations can help confirm eligibility criteria and provide referral guidance. These include the International Myeloma Foundation, HealthTree, and the Leukemia & Lymphoma Society.

Inside the 2-3 Month Referral-to-Infusion Timeline

From the time a referral is accepted to the day of infusion, the process typically takes 2 to 3 months. The exact length varies by center and by how urgently the disease needs treatment. Several steps fill that time:

1. Insurance authorization
2. Organ function testing to confirm the patient can safely receive treatment
3. Apheresis, the procedure that collects the patient’s T cells
4. Manufacturing, which can take up to about six weeks for cilta-cel
5. Bridging therapy, which is often used to control the disease while the cells are manufactured

During bridging, care teams generally avoid high-dose chemotherapy, because it can reduce T-cell yield and weaken CAR-T outcomes. A one- to two-week washout period before both apheresis and infusion is recommended. BCMA-directed drugs are also avoided as bridging therapy before a BCMA-targeted CAR-T.

The waiting-list crisis that once worried patients has largely eased. Between 2021 and 2023, median waits stretched to about six months, and only a fraction of waitlisted patients were ultimately treated. In 2026, some clinicians report no meaningful backlog, and manufacturing turnaround times continue to shorten.

What Happens After Infusion: Monitoring, Recovery, and Warning Signs

Both approved products can cause cytokine release syndrome (CRS), an inflammatory reaction that can include fever and drops in blood pressure. They can also cause neurologic effects known as immune effector cell-associated neurotoxicity syndrome (ICANS). These reactions can be serious and require monitoring by specialists trained to manage them.

Other possible complications include:

• Prolonged cytopenias (low blood counts)
• Hypogammaglobulinemia (low antibody levels)
• Increased infection risk
• Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), a rare but potentially life-threatening condition

Timing is an important consideration. Some side effects appear within 30 days of infusion, while others can emerge 90 days or more afterward. For this reason, patients and caregivers should stay in close contact with the treating center well after the initial recovery period.

Patients or caregivers should call the care team right away if any of these appear:

• Personality changes
• Neurologic or sensory changes
• New weakness
• New-onset diarrhea

Full recovery generally takes four to six weeks. In some patients, however, low blood counts can take up to three months to return to normal. Some centers now offer outpatient CAR-T with daily monitoring for eligible patients, rather than requiring a hospital stay.

CAR-T or Bispecific Antibodies First? A Sequencing Question Worth Asking

Bispecific antibodies are another type of immunotherapy. Like CAR-T, many of them target BCMA, and they work by linking the patient’s T cells directly to myeloma cells. Because both treatments target the same protein, the order in which they are given can affect long-term results.

Current evidence and emerging expert consensus favor giving CAR-T before bispecific antibodies when possible. Patients who respond to CAR-T often remain sensitive to BCMA-targeted bispecifics if the disease returns. In these sequences, progression-free survival (the time a patient lives without the disease worsening) has exceeded 18 months. Outcomes are generally worse when bispecifics are given first.

Two sources support this approach. A large real-world European cohort study of 640 patients linked CAR-T-first sequencing to better outcomes. Guidance from the International Myeloma Working Group Immunotherapy Committee also addresses sequencing these therapies.

Patients can raise the topic directly: “Given both options exist, is there a reason to sequence CAR-T before a bispecific, or vice versa, in my case?”

Financial and Logistical Planning: Building a Support System Early

CAR-T involves substantial costs and complex insurance coordination. Financial and logistical planning should begin at the same time as clinical preparation, not after.

Coverage and Certification

Medicare fee-for-service covers CAR-T products for FDA-approved uses. However, the facility giving the treatment must be certified under the manufacturer’s Risk Evaluation and Mitigation Strategy (REMS) program. This requirement is one reason only certain centers can provide CAR-T, and it is why a referral to the right center matters.

Drug Cost Protections

The Inflation Reduction Act set an annual out-of-pocket cap on Medicare Part D drug costs. Eligible patients can also choose to pay in monthly installments instead of all at once. Patients should discuss how these protections apply to them with a financial counselor.

Connecting With the Support Team Early

Patients should meet the treatment center’s financial counselor and patient navigator as early as possible. These professionals can coordinate insurance authorization, identify travel and lodging assistance, and help plan caregiver logistics while the medical workup is underway.

Pre-Referral Checklist

• Caregiver availability: Most centers require a caregiver for about 30 days after infusion.
• Lodging: Patients usually must stay within about 45 minutes of the center during that period.
• Work and leave plans: Patients and caregivers should clarify disability or leave options with their employers.
• Insurance documentation: Gather policy details and prior authorizations before the first evaluation appointment.

Requirements vary by program, so patients should confirm specifics with their chosen center.

The Road Ahead: What’s Changing in CAR-T Access and Technology

The contrast between the past and the present is reassuring. From 2021 to 2023, limited manufacturing slots led to median waits of about six months. In 2026, clinicians report that these bottlenecks have eased considerably. Patients with outdated fears about long waitlists may find that the process today is much faster.

Newer products may speed things up further. Anitocabtagene autoleucel (anito-cel) showed a manufacturing turnaround of 14 to 17 days in the iMMagine-1 trial. Gilead completed its acquisition of Arcellx in April 2026 to gain full control of the product. Anito-cel has an FDA decision expected on December 23, 2026, initially as a fourth-line treatment.

The broader treatment landscape is also expanding. In addition to CAR-T, BCMA can now be targeted by bispecific antibodies and antibody-drug conjugates. CAR-T products developed in China, such as equecabtagene autoleucel and zevorcabtagene autoleucel, are also in development. These advances may widen future options and change how treatments are sequenced.

The practical takeaway is clear: patients evaluated today benefit from a faster, more established referral pathway than patients did just a few years ago. That progress should encourage early referral conversations.

Conclusion: The Referral Roadmap Starts With One Conversation

Patients can become eligible for CAR-T earlier than many realize, and the timing of a referral can shape both outcomes and later treatment options. The roadmap is straightforward:

1. Know the eligibility triggers, such as lenalidomide-refractory disease, anti-CD38-refractory disease, high-risk cytogenetics, or early relapse.
2. Raise the referral conversation proactively using specific language.
3. Understand the realistic 2-3 month timeline and the steps within it.
4. Prepare caregiver, housing, and financial logistics early.
5. Stay engaged with the care team after infusion, including months later.

Self-advocacy, asking direct questions and requesting an evaluation, is a legitimate and often necessary part of accessing this therapy in time to benefit from it. Patients and caregivers who understand this roadmap are better positioned to act decisively rather than reactively.

Next Steps: Taking the CAR-T Referral Journey Forward

Readers can bring the referral triggers and sample questions from this article to their next oncology appointment. Writing them down in advance makes the conversation easier and more focused.

Patients and families who want more personalized guidance can turn to trusted health information resources, including resources such as Adiamed. Advocacy organizations such as the International Myeloma Foundation, HealthTree, and the Leukemia & Lymphoma Society also offer support.

Wherever a patient is in their treatment timeline, the most important first step is early action. Even scheduling a single evaluation conversation can open doors that might otherwise close.